Newsroom

CHARLOTTE, N.C.--(BUSINESS WIRE)--Hayward Holdings, Inc. (NYSE: HAYW) (“Hayward,” the “Company,” “we,” “us,” or “our”), a leading global specialty water management company focused on designing and manufacturing pool and outdoor living technology and industrial flow control products, today announced financial results for the third quarter of fiscal year 2026, ended September 26, 2026. Comparisons are to financial results for the prior-year third fiscal quarter. CEO COMMENTS “Hayward delivered an...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o...

SAN JOSE, Calif.--(BUSINESS WIRE)--Tula Technology signed a non-exclusive IP license agreement with a global Tier 1 automotive supplier covering the supplier’s entire E-drive portfolio....

HOUSTON--(BUSINESS WIRE)--Magnolia Oil & Gas Announces Quarterly Dividend...

NEW YORK--(BUSINESS WIRE)--TOMS Capital Investment Management (“TCIM”), which manages funds that together have an investment representing an approximately 4.65% economic interest in Voya Financial, Inc. (NYSE: VOYA) (“Voya” or the “Company”), today released an investor presentation detailing the case for shareholders to consider and vote on a non-binding resolution. This non-binding resolution allows shareholders to convey unequivocally that they “no longer continue to have confidence in the bo...

PHILADELPHIA & BOSTON--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company engineering gene therapies at scale, today announced the publication of a peer-reviewed study in Nature Communications, titled “Computational modeling and preclinical evaluation support targeting somatic instability for Huntington’s disease treatment.” The study was authored by multiple Latus scientists and led by co-corresponding authors Jang-Ho J. Cha, M.D., Ph.D. and Beverly L. Davidson, Ph.D. The public...

LIVONIA, Mich.--(BUSINESS WIRE)--Masco Corporation (NYSE: MAS), one of the world’s leading manufacturers of branded home improvement and building products, reported its third quarter 2026 results. 2026 Third Quarter Results On a reported basis, compared to the third quarter 2025: Net sales increased 3 percent to $1,966 million; in local currency and excluding our divestiture of Bristan, net sales increased 4 percent Plumbing Products’ net sales increased 4 percent; in local currency and excludi...

NEW YORK & SAN DIEGO--(BUSINESS WIRE)--KKR (NYSE: KKR), a leading global investment firm, and Alexandria Real Estate Equities, Inc. (NYSE: ARE), the leading owner, operator and developer of life science and advanced technology real estate, today announced a $475 million joint venture investment by capital accounts advised by KKR in Alexandria’s majority ownership interest in Campus Point by Alexandria Megacampus™, a nearly 2 million-square-foot life science Megacampus in San Diego, California....

PALO ALTO, Calif. & OSAKA, Japan--(BUSINESS WIRE)--D-Wave Quantum Inc. (NASDAQ: QBTS) ("D-Wave"), the only dual-platform quantum computing company providing both annealing and gate-model systems, software and services, today announced that its customer Shionogi & Co., Ltd. (“Shionogi”) has won first place in the Quality of Life (QOL) category of the NEDO Challenge for its research exploring the application of quantum computing to drug discovery. The award-winning research includes, among ot...

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that it has entered into a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate the use of Novocure’s Tumor Treating Fields (TTFields) therapy with chemotherapy and VS-7375, Verastem’s investigational oral, potent and selective KRAS G12D (ON/OFF) inhibitor, to treat locally advanced pancreatic cancer. “Meaningful progress has been made in the treatment of pancreatic cancer and we are prou...